Sponsor Spotlight – Harrow, Inc.

ABO was pleased to collaborate with Harrow, Inc. on our spring webinar No Tears Left to Cry: Restoring the Ocular Surface, presented by Laura Goldberg, OD. A special follow-up webinar with Steven Sorkin, OD, is scheduled for May 12 and will further explore Dry Eye Disease (DED) and VEVYE®.

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. 

Harrow also offers a comprehensive portfolio of products that address conditions affecting both the anterior and posterior segments of the eye, including dry eye disease, allergic conjunctivitis, ocular surface disease, neovascular age-related macular degeneration, and diabetic macular edema, among others. 

Founded with a commitment to deliver safe, effective, accessible, and affordable medications, Harrow focuses on solutions that enhance patient compliance and improve clinical outcomes. Harrow is also committed to supporting mission trips. In 2025, Harrow committed to donations helping nearly 5,000 patients in over 18 countries. 

Harrow Access for All is committed to addressing everyday unmet needs for providers and patients nationwide. This focused approach prioritizes reliability, consistency, and clinical relevance, ensuring that we remain a trusted partner to eye care professionals and deliver steady, predictable performance. By bringing together select branded and compounded solutions under a single, integrated commercial team, Access+ is designed to make it easier for eye care professionals to prescribe the medications their patients rely on most—improving access, affordability, and continuity of care while reducing friction for both providers and patients. 

Harrow’s portfolio includes: 

Dry Eye Disease 
• VEVYE® (cyclosporine ophthalmic solution 0.1%) 
• FLAREX® (fluorometholone acetate ophthalmic suspension 0.1%) 
• FRESHKOTE® – Preservative-Free Lubricant Eye Drops 

Anesthetics 
• IHEEZO® (chloroprocaine HCl ophthalmic gel 3%) 

Antibiotics 
• VIGAMOX® (moxifloxacin HCl ophthalmic solution 0.5% as base) 
• MAXITROL® (neomycin, polymyxin B sulfates & dexamethasone ophthalmic suspension) 

Ocular Allergies 
• ZERVIATE® (cetirizine ophthalmic solution 0.24%) 

Vernal Keratoconjunctivitis 
• VERKAZIA® (cyclosporine ophthalmic emulsion 0.1%) 

Anti-Fungal 
• NATACYN® (natamycin ophthalmic suspension 5%) – Anti-Fungal, Rx Only 

Pain 
• NEVANAC® (nepafenac ophthalmic suspension 0.1%) 
• ILEVRO® (nepafenac ophthalmic suspension 0.3%) 

Steroids 
• TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) 
• BYQLOVI™ (clobetasol propionate ophthalmic suspension 0.05%) 
• MAXIDEX® (dexamethasone ophthalmic suspension 0.1%) 

Anti-VEGF 
• BYOOVIZ® (ranibizumab-nuna 0.05 mL injection) – mid-2026 launch 
• OPUVIZ™ (aflibercept-yszy 0.05 mL injection) – January 2027 launch 

Combination Products 
• Proprietary compounded products for accessible & affordable everyday needs 

IOP Control 
• IOPIDINE® (apraclonidine hydrochloride ophthalmic solution) 

Sedation Drug Candidates 
• G-MELT (oral disintegrating tablet (ODT) combining 3 mg midazolam + 50 mg ketamine) for IV- and opioid-free procedural sedation (launch expected in 2028) 
• YOCHIL (3 mg midazolam ODT) for sedation, anxiolysis, and amnesia 

Thank you to Harrow, Inc. for supporting ABO’s mission to advance the quality of eye care by promoting excellence through lifelong learning. For more information about Harrow, please visit harrow.com.